Patent Application for Free LIGHT Detection and Treatment

ChangeBridge: Patent Apps - Peptides (C07K)

Detected March 26th, 2026

Summary

The USPTO has published a patent application (US20260085112A1) from Avalo Therapeutics, Inc. for methods of detecting and treating conditions associated with elevated free LIGHT using anti-LIGHT antibodies. The application covers methods for diagnosing conditions like acute lung injury, ARDS, and Crohn's Disease.

View original document View source feed page

What changed

This document is a published patent application from Avalo Therapeutics, Inc. detailing methods for detecting and treating conditions related to elevated free LIGHT. The application, identified as US20260085112A1, describes diagnostic techniques for biological samples and therapeutic approaches using anti-LIGHT antibodies. Specific conditions mentioned include acute lung injury (ALI), acute respiratory distress syndrome (ARDS), and Crohn's Disease, with potential applications in viral infections.

As this is a patent application, it does not impose immediate regulatory obligations on companies. However, it signals potential future developments in diagnostics and therapeutics within the pharmaceutical and biotechnology sectors. Companies involved in related research or treatment areas should monitor the progress of this patent application and any subsequent granted patents, as they may impact intellectual property landscapes and market exclusivity for certain treatments.

Source document (simplified)

← USPTO Patent Applications

Methods and Treatment Involving Excess Free LIGHT

Application US20260085112A1 Kind: A1 Mar 26, 2026

Assignee

Avalo Therapeutics, Inc.

Inventors

Garry A. Neil, Inbal Zafir-Lavie

Abstract

The present disclosure relates to methods of detecting free (active) LIGHT in biological samples to diagnose conditions associated with elevated free LIGHT, as well as to predict the effectiveness of anti-LIGHT therapies. The disclosure also relates to treating such conditions with anti-LIGHT antibodies. Conditions include acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), optionally wherein the ALI and ARDS are associated with viral infection, including coronavirus infection. Conditions also include Crohn's Disease or an inflammatory condition associated with Crohn's Disease.